Skip to Content

Abarelix

In the US, Abarelix (abarelix systemic) is a member of the following drug classes: gonadotropin-releasing hormone antagonists, hormones/antineoplastics and is used to treat Prostate Cancer.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L02BX01

CAS registry number (Chemical Abstracts Service)

0183552-38-7

Chemical Formula

C72-H95-Cl-N14-O14

Molecular Weight

1416

Therapeutic Categories

Cytostatic agent

Gonadotropin releasing hormone (GnRH) receptor antagonist

Chemical Name

N-Acetyl-3-(2-naphtyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-metyl-L-tyrosyl-D-asparaginyl-L-leucyl-N⁶-isopropyl-L-lysyl-L-prolyl-D-alaninamide (WHO)

Foreign Names

  • Abarelixum (Latin)
  • Abarelix (German)
  • Abarelix (French)
  • Abarelix (Spanish)

Generic Names

  • Abarelix (OS: USAN)
  • PPI 149 (IS: Praecis)
  • R 3827 (IS: Praecis)

Brand Names

  • Plenaxis
    EuroCept, Netherlands; Speciality European Pharma, Germany

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide